Director of the Brigham Diabetes Program at the Brigham and Women's Hospital discusses the latest in diabetes management.
Among chronic conditions reaching epidemic proportions worldwide, diabetes, and type 2 diabetes (T2D) in particular, is notable for the remarkable burden it exacts on individuals, their families, and on the healthcare system at large.
Just as notable, however, is the rapid growth in available therapies and in the technology used to monitor and manage response to those therapies.
Dr Marie McDonnell, an endocrinologist and director of the Brigham Diabetes Program at Brigham and Women’s Hospital and a lecturer at Harvard Medical School, was interviewed recently by our sister site Medical Economics, on these topics and her thoughts on the future of T2D care.
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.